<DOC>
	<DOCNO>NCT00157586</DOCNO>
	<brief_summary>Diabetes mellitus one common diseases globally , consider epidemic many develop newly industrialize nation . Diabetes mellitus represent single large cause end-stage renal disease U.S. Europe . At time , primary cause early death diabetic patient cardiovascular complication . Experimental clinical study find angiotensin convert enzyme inhibitor ( ACEi ) calcium channel blocker ( CCBs ) specific renoprotective effect effect magnify two drug use combination . To formally test hypothesis design Delapril Manidipine Nephroprotection Diabetes ( DEMAND ) study , prospective , randomize , double blind trial aim compare effect 3 year treatment ACEi Delapril ( 30 mg/day ) , alone combine CCB Manidipine ( 10 mg/day ) , versus conventional ( non ACEi , non CCB ) therapy rate renal function loss incidence major cardiovascular event 342 normo- micro-albuminuric hypertensive type 2 diabetic patient .</brief_summary>
	<brief_title>Delapril Manidipine Nephroprotection Diabetes ( DEMAND )</brief_title>
	<detailed_description>INTRODUCTION Optimal blood pressure , glycemic lipid control utmost importance minimize incidence progression chronic renal cardiovascular complication patient diabetes mellitus type 2 . Whether angiotensin convert enzyme ( ACE ) inhibitor alone combine calcium channel blocker ( CCB ) may reduce incidence progression chronic complication worth investigate . AIMS The primary aim study ass whether comparable level optimal blood pressure metabolic control , ACE inhibitor delapril alone combination dihydropyridine CCB manidipine slow rate glomerular filtration rate ( GFR ) decline compare placebo plus conventional antihypertensive therapy patient diabetes mellitus type 2 hypertension . The secondary aim study assess effect delapril manidipine incidence major cardiovascular event ( acute myocardial infarction , ictus stroke , heart failure require hospitalization , revascularization , amputation cardiovascular mortality ) . STUDY POPULATION 342 hypertensive type 2 diabetes patient normo- micro-albuminuria . STUDY DESIGN This multicenter , prospective , randomize , double-blind , placebo-controlled study . After 12-week baseline period prohibit antihypertensive treatment ( ACE inhibitor , angiotensin II receptor antagonist dihydropyridine calcium channel blocker ) discontinue , patient stratify accord urinary albumin excretion rate normo- micro-albuminuric randomize delapril alone ( 30 mg/day ) , delapril ( 30 mg/day ) combine manidipine ( 10 mg/day ) placebo give daily morning least three year . During study , systolic diastolic blood pressure treatment group maintain ≤ 120 80 mmHg respectively , fix dos study treatment flexible dos permit antihypertensive therapy ( diuretic , beta blocker , alfa blocker , centrally act adrenergic blocker . Blood pressure , blood glucose concentration urinary albumin excretion rate monitor every three month . Serum lipid concentration GFR ( estimate iohexol plasma clearance ) measure every six month . Primary Secondary Variables . The primary efficacy variable study rate GFR decline . The secondary efficacy variable incidence major cardiovascular event ( acute myocardial infarction , ictus stroke , heart failure require hospitalization , revascularization , amputation cardiovascular mortality ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Delapril</mesh_term>
	<mesh_term>Manidipine</mesh_term>
	<criteria>Age ≥ 40 year History diabetes mellitus type 2 least three month stable antidiabetic treatment Systolic and/or diastolic blood pressure ≥ 135 85 mmHg , respectively . In alternative , antihypertensive therapy regardless blood pressure value Serum creatinine ≤ 1.5 mg/dL Urinary albumin excretion rate &lt; 200 µg/min Written inform consent trial participation . Clinical histological evidence nondiabetic renal disease , include vascular disease kidney , obstructive uropathy , prostatic hypertrophy incomplete bladder empty Transplanted kidney Moderate severe chronic heart failure ( IIIIV stage accord NYHA classification ) . Cerebral hemorrhage , stroke transient ischemic attack within three month prior trial enrolment Myocardial infarction within three month prior trial enrolment Unstable angina pectoris Mitral valve stenosis , aortic stenosis hypertrophic cardiomyopathy Secondary ( e.g. , Cushing disease , phaeochromocytoma , etc . ) severe refractory hypertension Poor glycemic control ( HbA1c &gt; 11 % ) Connective tissue autoimmune disease Hereditary angioneurotic edema Clinically relevant electrolyte imbalance ( e.g. , serum potassium &gt; 5.5 mmol/L ) Clinically relevant hematological disorder Anemia hemoglobin concentration &lt; 10 g/dL Serious hepatic disease Pregnancy lactate plan pregnancy Women childbearing potential without follow scientifically accept form contraception Any serious terminal concomitant disease Any condition may interfere absorption study treatment Any concomitant treatment ACE inhibitor , angiotensin II blocker , calcium channel blocker , potassium spar diuretic Chronic treatment nonsteroidal antiinflammatory drug , antidepressant neuroleptic , lithium , cimetidine , immunosuppressive and/or antineoplastic drug , chronic systemic glucocorticoid therapy 7 consecutive day one month , antiarrhythmic drug ( e.g. , chinidin , procainamide ) , anesthetics/narcotics History hypersensitivity delapril ACE inhibitor , manidipine dihydropyridine CCBs Legal incapacity and/or circumstance render patient unable understand nature , scope possible consequence trial Evidence uncooperative attitude Any evidence allows predict patient able complete trial followup .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2006</verification_date>
</DOC>